AUTHOR=Orena Stephen , Maurer Tristan , Eudy Rena , She Li , Dash Darla , Loria Paula , Banker Mary Ellen , Bernardo Vincent , Tugnait Meera , Okerberg Carlin , Qian Jessie , Boustany-Kari Carine M. TITLE=PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy JOURNAL=Frontiers in Pharmacology VOLUME=4 YEAR=2013 URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2013.00115 DOI=10.3389/fphar.2013.00115 ISSN=1663-9812 ABSTRACT=
The mineralocorticoid receptor (MR) antagonists PF-03882845 and eplerenone were evaluated for renal protection against aldosterone-mediated renal disease in uninephrectomized Sprague-Dawley (SD) rats maintained on a high salt diet and receiving aldosterone by osmotic mini-pump for 27 days. Serum K+ and the urinary albumin to creatinine ratio (UACR) were assessed following 14 and 27 days of treatment. Aldosterone induced renal fibrosis as evidenced by increases in UACR, collagen IV staining in kidney cortex, and expression of pro-fibrotic genes relative to sham-operated controls not receiving aldosterone. While both PF-03882845 and eplerenone elevated serum K+ levels with similar potencies, PF-03882845 was more potent than eplerenone in suppressing the rise in UACR. PF-03882845 prevented the increase in collagen IV staining at 5, 15 and 50 mg/kg BID while eplerenone was effective only at the highest dose tested (450 mg/kg BID). All doses of PF-03882845 suppressed aldosterone-induced increases in collagen IV, transforming growth factor-β 1 (